9/3/08		SANDOZ RECEIVES FDA APPROVAL FOR OMNITROPE® PEN 10 WITH LIQUID CARTRIDGE New 10mg strength offers increased treatment flexibility and more convenient dosage form Comparable quality, safety and efficacy combined with significant cost savings Approval further demonstrates Sandoz leadership in high quality follow-on biologics more
6/24/08		SANDOZ LAUNCHES GENERIC VERSION OF ALTACE® Sandoz today announced the introduction of ramipril capsules, a generic equivalent of Altace®, in the United States. more
5/22/08		SANDOZ ENTERS INTO MARKETING AND DISTRIBUTION AGREEMENT WITH LNK INTERNATIONAL FOR GENERIC ZYRTEC® PRODUCTS Sandoz announced today a supply agreement with LNK International whereby LNK will market and distribute cetirizine hydrochloride/ pseudoephedrine hydrochloride, cetirizine hydrochloride tablets and cetirizine hydrochloride chewable tablets in retailers' own store brand packaging. more
5/21/08		SANDOZ LAUNCHES GENERIC VERSION OF MAXIPIME® Sandoz today announced the introduction of cefepime hydrochloride injection, a generic equivalent of Maxipime®, in the United States. more
4/30/08		SANDOZ RECEIVES REGULATORY GUIDANCE ON ENOXAPARIN ANDA Sandoz, the generics division of Novartis AG, today announced that the Food and Drug Administration (FDA) has provided guidance regarding its abbreviated new drug application (ANDA) for enoxaparin. more
4/2/08		SANDOZ LAUNCHES GENERIC VERSION OF ANTIZOL® INJECTION Sandoz today announced the introduction of fomepizole injection, a generic equivalent of Antizol®, in the United States. more
3/26/08		SANDOZ LAUNCHES COSYNTROPIN LIQUID INJECTION Sandoz today announced the introduction of cosyntropin injection in the United States. more
3/20/08		SANDOZ RE-INTRODUCES GENERIC VERSION OF BACTOCILL® INJECTION IN ADD-VANTAGE® VIALS Sandoz today announced the re-introduction of oxacillin sodium injection, a generic equivalent of Bactocill® in ADD-Vantage vials®, in the United States. more
3/19/08		SANDOZ LAUNCHES GENERIC VERSION OF CIPRO® INJECTION Sandoz introduced ciprofloxacin injection, a generic equivalent of Cipro®, in the United States today. more
3/12/08		SANDOZ ENHANCES PATIENT ACCESS WITH LAUNCH OF OMNITROPE™ PEN 5 WITH LIQUID CARTRIDGE Sandoz today announced the introduction in the United States of Omnitrope™ Pen 5 with liquid cartridge, a new form of the first follow-on version of a previously approved recombinant biotechnology drug approved by the Food and Drug Administration. more
3/6/08		SANDOZ LAUNCHES GENERIC VERSION OF ZYRTEC-D® Sandoz introduced cetirizine hydrochloride/pseudoephridine hydrochloride, a generic version of Zyrtec-D®, in the United States today. more
2/27/08		SANDOZ LAUNCHES GENERIC VERSION OF CAMPTOSAR® Sandoz introduced irinotecan hydrochloride, a generic equivalent of Camptosar®, in the U.S. today. more
1/22/08		SANDOZ RECEIVES FDA APPROVAL FOR OMNITROPE™ PEN 5 WITH LIQUID CARTRIDGE Sandoz has received final US Food and Drug Administration approval for its Omnitrope™ Pen 5 with liquid cartridge. more
11/28/07		SANDOZ LAUNCHES GENERIC VERSION OF ELOCON® LOTION Sandoz introduced mometasone furoate, a generic equivalent of Elocon® lotion, in the U.S. recently. more
10/25/07		SANDOZ EXPANDS WILSON, NORTH CAROLINA OPERATIONS Sandoz, a leading generic pharmaceutical company, completed the major phase of its Wilson, North Carolina expansion when over 50 employees moved into a new 30,000 square foot building recently. more
10/04/07		SANDOZ LAUNCHES GENERIC VERSION OF DELESTROGEN® INJECTIONS Sandoz introduced estradiol valerate, a generic equivalent of Delestrogen® injections, in the U.S. today. more
10/01/07		SANDOZ EXTENDS LINE OF GENERIC AUGMENTIN® MEDICINES Sandoz introduced an extension of its line of amoxicillin and clavulanate potassium for oral suspension, a generic equivalent of Augmentin ES-600®, in the U.S. recently. more
9/21/07		SANDOZ LAUNCHES GENERIC VERSION OF BIAXIN® FOR ORAL SUSPENSION Sandoz introduced clarithromycin for oral suspension, a generic equivalent of Biaxin®, in the U.S. this week. more
9/18/07		SANDOZ LAUNCHES GENERIC VERSION OF PENLAC® TOPICAL SOLUTION Sandoz introduced ciclopirox topical solution, a generic equivalent of Penlac®, in the U.S. today upon the expiration of patent protection on the original product. more
8/02/07		SANDOZ LAUNCHES GENERIC VERSION OF TOPROL XL® 50 MG ER TABLET Sandoz introduced metoprolol succinate 50 mg extended release tablets, a generic equivalent of Toprol XL®, in the U.S. today. more
7/02/07		SANDOZ LAUNCHES AUTHORIZED GENERIC VERSION OF LAMISIL® Sandoz introduced terbinafine hydrochloride, a generic version of Lamisil®, in the U.S. today. more
6/29/07		SANDOZ LAUNCHES GENERIC VERSION OF MAVIK® Sandoz introduced trandolapril, a generic equivalent of Mavik®, in the U.S. recently. more
6/11/07		SANDOZ LAUNCHES AUTHORIZED GENERIC VERSION OF LOTREL® Sandoz introduced amlodipine besylate/benazepril capsules, an authorized generic equivalent of Lotrel®, in the U.S. today. more
5/21/07		SANDOZ RECEIVES FDA APPROVAL FOR GENERIC TOPROL XL® 50 MG TABLET Sandoz announced today that the US Food and Drug Administration has granted final approval to its abbreviated new drug application for metoprolol succinate 50 mg extended release tablets, a generic equivalent of Toprol XL®. more
5/31/06		SANDOZ GETS PRECEDENT-SETTING US APPROVAL FOR OMNITROPE® HOLZKIRCHEN, Germany, May 31, 2006 - Sandoz announced today that the US Food and Drug Administration has granted approval for the company’s recombinant human growth hormone Omnitrope® as the first follow-on version of a previously approved recombinant biotechnology drug in the US. more
7/19/05		SANDOZ TO LAUNCH GENERIC CEFTRIAXONE INJECTION® PRINCETON, NEW JERSEY, July 19th 2005 - Sandoz Inc., a Novartis company and one of the leading generic pharmaceutical companies in the world, announced today it will launch its version of generic Ceftriaxone Injection. more
8/16/04		NOVARTIS COMPLETES SABEX ACQUISITION - Provides strong growth opportunities in generic injectables market BASEL, August 16th 2004 - Novartis AG announced today that its Sandoz generics business unit has completed the acquisition of Sabex Holdings Ltd., a leading Canadian generics pharmaceutical manufacturer in a USD 565 million cash transaction that officially closed on August 13. Sabex was acquired from the US private equity firm RoundTable Healthcare Partners, which had held a majority stake in the company. more
7/9/04		SANDOZ INC. AND ALARA PHARMACEUTICALS PREVAIL IN LEVOTHYROXINE SUIT - Companies Continue to Provide AB-Rated Bioequivalent Hypothyroid Product - PRINCETON, NEW JERSEY, July 9, 2004. Sandoz Inc., a Novartis company and one of the leading generic pharmaceutical companies in the world, announced today that King Pharmaceuticals, Inc. and Jones Pharma, Inc. (together, Jones) were defeated in their motion for a temporary restraining order and preliminary injunction against the United States Food and Drug Administration (FDA) with respect to Alara Pharmaceutical Corporation's (Alara's) Levothyroxine Sodium tablets, which are sold exclusively by Sandoz. more
6/23/04		Sandoz Inc. launches AB-Rated Levothyroxine PRINCETON, NEW JERSEY, June 23, 2004. Sandoz Inc., a Novartis company and one of the leading generic pharmaceutical companies in the world, announced today it began commercially shipping its version of generic Levothyroxine sodium tablets. more
6/7/04		Sandoz makes major entry into generic injectables field with acquisition of fastgrowing Sabex Holdings Ltd. of Canada VIENNA, AUSTRIA, June 7, 2004. Sandoz, a Novartis company, today announced plans to acquire Sabex Holdings Ltd. in a USD 565 million cash transaction that will provide strong growth opportunities in injectable generics and new entry into the Canadian generics sector. The deal continues Sandoz strategy of building its global business through strong organic growth and strategic acquisitions that provide access to new geographic markets, therapeutic lines, formulations and production capabilities. more
4/7/04		SANDOZ INC. LAUNCHES GENERIC REBETOL® PRINCETON, NEW JERSEY, April 7, 2004. Sandoz Inc., a Novartis company announced today it is launching generic Rebetol® (Ribavirin). more
12/01/03		GENEVA PHARMACEUTICALS, INC., RENAMED SANDOZ, INC. PRINCETON, NEW JERSEY, December 1, 2003. Geneva Pharmaceuticals, Inc., a Novartis company and one of the leading Generic pharmaceutical companies in the U.S., announced it will be conducting its operations under the company name Sandoz, Inc., effective Dec. 1, 2003. more
12/01/03		History of Sandoz more
11/18/03		Strategic Alliance with Momenta Pharmaceuticals Momenta Pharmaceuticals and Sandoz, Inc. Form Strategic Alliance for the Application of Breakthrough Sugar Technology to Product Development more